HypoxiaPlanHabNCT02293772
Planetary Habitat Simulation: Nutrition Studies
A study testing Hypoxic ambulatory, Hypoxic Bedrest and Normoxic Bedrest in people with Hypoxia, run by University of Nottingham.
Trial summary
A loss of body weight has been documented in lowland-living individuals when exposed to hypoxic environments, such as at high altitude, or under laboratory conditions. A reduction in appetite and energy intake has also been reported during conditions of microgravity, such as during space flight. Read more about this study
- Who is it for?
- Ages 25 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Hypoxia
- What is being tested?
- Hypoxic ambulatory, Hypoxic Bedrest and Normoxic Bedrest
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 14 participants
- Where
- No sites listed yet
- Study dates
- Mar 2012to Oct 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Physically and mentally healthy subjects
- Body mass index < 25 kg/m2
- Height 158 - 190 cm
- Waist circumference < 94 cm
- Volunteers that are able to declare their willingness to participate in the entire study
- Willing to be assigned randomly to the three groups
Show all 10Show fewer
- Successfully passing the psychological and medical screening
- competent to sign informed consent
- Slovenian social insurance
- English language fluency
Who cannot join
- Medication required that may interfere with the interpretation of the results
- Bone mineral density (as measured by DEXA) more than 1.5 standard deviations < t score
- Recent sub-standard nutritional status
- Family history of thrombosis or positive response in thrombosis screening procedure.
- (Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor II)
- History of: thyroid dysfunction, renal stones, diabetes, allergies, hypertension, hypocalcemia, uric acidaemia, lipidaemia, or hyperhomocysteinaemia
Show all 20Show fewer
- Gastro-esophageal reflux disease or renal function disorder, Hiatus hernia
- History of medical illness
- Smoker within six months prior to the start of the study
- Abuse of drugs, medicine or alcohol
- Participation in another study up to two months before study onset
- No signed consent form before the onset of the experiment
- Blood donors in the past three months before the onset of the experiment
- Vegetarian and Vegans
- Migraines
- History of orthostatic intolerance
- History of vestibular disorders
- Claustrophobia
- metallic implants, osteosynthesis material
- Chronic back pain
About this study
Official title: Planetary Habitat Simulation: An Investigation Into the Effects of Hypoxia and / or Bedrest on Fuel Metabolism and Appetite (WP5)
A loss of body weight has been documented in lowland-living individuals when exposed to hypoxic environments, such as at high altitude, or under laboratory conditions. A reduction in appetite and energy intake has also been reported during conditions of microgravity, such as during space flight. Fourteen normal or over-weight men, who are otherwise healthy, will undergo 3x 21-day interventions; normobaric normoxic bed rest (NBR; FiO2=21%), normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and normobaric hypoxic bed rest (HBR; FiO2=14%). The effects of hypoxia and bedrest on appetite and its hormonal control will be assessed before and at day 17 of each intervention using a mixed meal tolerance test.
Read the detailed description
A loss of body weight has been documented in lowland-living individuals when exposed to hypoxic environments, such as at high altitudes, or under laboratory conditions. This weight loss has been attributed both to a reduced appetite (and subsequent fall in dietary energy intake), and to an increase in resting energy expenditure. Interestingly, a reduction in appetite and energy intake has also been reported during space flight, although the mechanism for this has not been explained. As the gas inside future planetary habitats is likely to have lower partial pressure of oxygen than in Earth's atmospheric air, hypoxia induced appetite reduction could pose a challenge for individuals in these environments. For example, persistent under-eating could compromise long term health due to inadequate intake of essential micronutrients, especially in the presence of altered nutrient metabolism and requirements seen during space flight. Moreover, inadequate macronutrient intake could exacerbate the loss of lean body tissue which occurs in situations (such as microgravity, inactivity and bed rest) where muscles are unloaded. Indeed, a protein intake greater than normal could be required in situations where there is muscle inactivity, to achieve the same postprandial anabolic effect of amino acids seen in ambulatory individuals.
The mechanism for the reduction in appetite observed in hypoxia is not well established. Several incretin hormones and adipokines have been implicated in the control of appetite and may be candidates for inducing this alteration in appetite observed in hypoxia. However, reports in the literature present contradictory findings, perhaps due to the use of different experimental paradigms (hypobaric and normobaric hypoxia, active and resting subjects, variability in the degree and duration of hypoxia).
The protocol of the current study standardises physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the diet, and aims to extend our knowledge of the effects of hypoxia and bedrest on appetite and its hormonal control.
In order to discern the separate and combined effects of microgravity and hypoxia, fourteen normal or over-weight men, who are otherwise healthy, will be recruited following medical and psychological screening. They will be invited to attend the Olympic Sport Centre, Planica, Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months. Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of intervention and a recovery period (5 days), with the 3 interventions allocated in a randomized, cross over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised of foods commonly consumed in the Slovenian diet, will be applied during all campaigns, the targeted energy intakes being calculated individually using a modified Benedict-Harris formula with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and 1.4 for the HAMB campaign. Food will be provided in weighed portions and subjects will be encouraged to eat all food supplied. However, any food not eaten will be weighed and actual amount consumed recorded in a diet analysis programme. Body mass will be assessed daily during the campaigns using a gurney incorporating load cells, and whole body composition will be determined before and immediately after each intervention using fan beam dual-emission X-ray absorptiometry.
Participants will undergo a mixed meal tolerance test before and on day 17 of each intervention period, in the morning, after a 12 hour fast, with the time of assessment replicated on each study day at every campaign. On arrival, participants will rest supine on a hospital bed and place their hand in a heated hand warming unit (air temperature 50-55oC). An intravenous cannula will then be inserted retrograde into a dorsal hand vein for arterialised-venous blood sampling. After 15mins rest, a baseline, fasting blood sample will be taken for determination of serum insulin, total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, adiponectin and leptin, whole blood glucose and lactate, and plasma catecholamines, ghrelin, PeptideYY (PYY), glucagon-like peptide-1(GLP-1), triglycerides, and non-esterified fatty acid concentration. An expired breath sample will be collected into evacuated tubes for 13 labelled carbon dioxide (13CO2) determination, and a 20min baseline measurement of resting energy expenditure (REE) and respiratory exchange ratio (RER) will be then made using indirect calorimetry, with subjects wearing a mask, and both inspired and expired air being measured on every breath. Appetite assessment will be made by asking subjects to rate their hunger, desire to eat, fullness, and their prospective food intake, by placing a vertical mark on a 0-100mm linear scale. This visual analogue scale will be measured from left to right, with 0 indicating no experience of the variable (e.g. not hungry, unable to eat anything) and 100 indicating the most of each variable that they can imagine experiencing (e.g. intense desire to eat, or completely full). Values for these 4 variables will be combined to calculate a combined appetite score (CAS). Once baseline measurements have been completed, subjects will consume a mixed nutrient milkshake (Ensure Plus, Abbott Nutrition) at 5ml/kg body weight, which will be supplemented (at 1% of carbohydrate content) with 13-Carbon labelled (13C) Glucose. Arterialised venous blood samples will subsequently be taken every 10min for glucose and lactate assessment, and every 20min for assessment of serum insulin and incretin hormones. A measurement of REE and RER will be performed in the last 15min of every 30min period for the following 2 hours to assess fuel oxidation and metabolic rate, and an expired breath sample will be collected into evacuated tubes for 13CO2 determination at a later date. Subjective appetite will be assessed every 15minutes throughout using visual analogue scales, as described above, and at the end of the 2hr postprandial period subjects will be given an ad libitum pasta-based test meal and will be instructed to eat until they feel comfortably full. This meal will be comprised of cooked dried white pasta, commercially available tomato-based pasta sauce, olive oil and grated hard cheese, with a composition of 37% of total energy derived from fat, 48% carbohydrate, and 16% protein. The amount eaten will be recorded and related to subjective appetite ratings.
- Conditions
- Hypoxia
- Being tested
- Hypoxic ambulatory, Hypoxic Bedrest, Normoxic Bedrest
- Keywords
- Bedrest, Appetite
- Medical subject headings
- Hypoxia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hypoxic ambulatoryOther
21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
Hypoxic BedrestOther
21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
Normoxic BedrestOther
21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
| Study group | Role | What they receive |
|---|---|---|
| Hypoxic ambulatory | Active comparator | Ambulatory in normobaric hypoxia Receives: Other: Hypoxic ambulatory |
| Hypoxic Bedrest | Experimental | Bedrest in normobaric hypoxia Receives: Other: Hypoxic Bedrest |
| Normoxic bedrest | Active comparator | Bedrest in normobaric normoxia Receives: Other: Normoxic Bedrest |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial whole blood glucose concentration
a fasted sample and a sample taken every 10mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Secondary outcomes (18)
Postprandial serum insulin concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Postprandial serum C-Peptide concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Fasting serum leptin concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting serum adiponectin concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting serum total cholesterol concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting serum LDL cholesterol concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting serum HDL cholesterol concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting plasmaTriacylglycerol concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Fasting plasma non-esterified fatty acids concentration
Early morning fasted sample taken before and on day 17 of intervention
Measured: early morning fasted sample
Postprandial plasma peptide YY concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Postprandial plasma Ghrelin concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Postprandial plasma GLP-1 concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Postprandial plasma catecholamine concentration
a fasted sample and a sample taken every 20mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
Postprandial whole blood lactate concentration
a fasted sample and a sample taken every 10mins for 2hrs following eating, before and after 17days of intervention
Measured: 2hrs
postprandial fuel oxidation
A fasted measurement of respiratory exchange ratio and measures between 15-30, 45-60min, 75-90min and 105-120min after eating, before and on day 17 of intervention
Measured: 2hrs
postprandial resting energy expenditure
A fasted measurement of resting energy expenditure and measures between 15-30, 45-60min, 75-90min and 105-120min after eating, before and on day 17 of intervention
Measured: 2hrs
postprandial subjective appetite
A fasted measurement of combined appetite score (measured using visual analogue scales), followed by assessment every 30min for 2hrs after eating, before and on day 17 of intervention.
Measured: 2hrs
postprandial expired 13CO2
Collection of breath samples when fasted and every 30min for 2hrs after eating, before and on day 17 of intervention.
Measured: 2hrs
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2014 (estimated)
- Study startMar 2012
- Primary completionNov 2013
- Study completionOct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for HypoxiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 14 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nottingham
- Sponsor type
- University, hospital or other
- Collaborators
- Jozef Stefan Institute, KTH Royal Institute of Technology, European Commission
- Responsible party
- Principal investigator, Elizabeth Simpson, University of Nottingham
- Investigators
- Igor Mekjavic, PhD, Principal investigator, Jozef Stefan Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02293772
- Sponsor's protocol ID
- 284438/WP5
- Acronym
- PlanHab
- Status last verified
- Mar 2019
- First submitted
- 13 Nov 2014
- Last updated
- 15 Mar 2019
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Simpson EJ, Debevec T, Eiken O, Mekjavic I, Macdonald IA. PlanHab: the combined and separate effects of 16 days of bed rest and normobaric hypoxic confinement on circulating lipids and indices of insulin sensitivity in healthy men. J Appl Physiol (1985). 2016 Apr 15;120(8):947-55. doi: 10.1152/japplphysiol.00897.2015. Epub 2016 Jan 14.
PubMed 26769956Debevec T, Bali TC, Simpson EJ, Macdonald IA, Eiken O, Mekjavic IB. Separate and combined effects of 21-day bed rest and hypoxic confinement on body composition. Eur J Appl Physiol. 2014 Nov;114(11):2411-25. doi: 10.1007/s00421-014-2963-1. Epub 2014 Aug 5.
PubMed 25091855Debevec T, Simpson EJ, Mekjavic IB, Eiken O, Macdonald IA. Effects of prolonged hypoxia and bed rest on appetite and appetite-related hormones. Appetite. 2016 Dec 1;107:28-37. doi: 10.1016/j.appet.2016.07.005. Epub 2016 Jul 6.
PubMed 27395413
Study at a glance
From the registry record, last updated by the sponsor on 15 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Planetary Habitat Simulation: An Investigation Into the Effects of Hypoxia and / or Bedrest on Fuel Metabolism and Appetite (WP5)
- ClinicalTrials.gov ID
- NCT02293772
- Acronym / sponsor ID
- PlanHab / 284438/WP5
- Conditions
- Hypoxia
- Keywords
- Bedrest, Appetite
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 14 participants (actual)
- Lead sponsor
- University of NottinghamUniversity, hospital or other
- Collaborators
- Jozef Stefan Institute, KTH Royal Institute of Technology, European Commission
- Study start
- Mar 2012
- Primary completion
- Nov 2013 (actual)
- Study completion
- Oct 2014 (actual)
- First posted
- 18 Nov 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A loss of body weight has been documented in lowland-living individuals when exposed to hypoxic environments, such as at high altitude, or under laboratory conditions. A reduction in appetite and energy intake has also been reported during conditions of microgravity, such as during space flight. Fourteen normal or over-weight men, who are otherwise healthy, will undergo 3x 21-day interventions; normobaric normoxic bed rest (NBR; FiO2=21%), normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and normobaric hypoxic bed rest (HBR; FiO2=14%). The effects of hypoxia and bedrest on appetite and its hormonal control will be assessed before and at day 17 of each intervention using a mixed meal tolerance test.
Detailed description
A loss of body weight has been documented in lowland-living individuals when exposed to hypoxic environments, such as at high altitudes, or under laboratory conditions. This weight loss has been attributed both to a reduced appetite (and subsequent fall in dietary energy intake), and to an increase in resting energy expenditure. Interestingly, a reduction in appetite and energy intake has also been reported during space flight, although the mechanism for this has not been explained. As the gas inside future planetary habitats is likely to have lower partial pressure of oxygen than in Earth's atmospheric air, hypoxia induced appetite reduction could pose a challenge for individuals in these environments. For example, persistent under-eating could compromise long term health due to inadequate intake of essential micronutrients, especially in the presence of altered nutrient metabolism and requirements seen during space flight. Moreover, inadequate macronutrient intake could exacerbate the loss of lean body tissue which occurs in situations (such as microgravity, inactivity and bed rest) where muscles are unloaded. Indeed, a protein intake greater than normal could be required in situations where there is muscle inactivity, to achieve the same postprandial anabolic effect of amino acids seen in ambulatory individuals.
The mechanism for the reduction in appetite observed in hypoxia is not well established. Several incretin hormones and adipokines have been implicated in the control of appetite and may be candidates for inducing this alteration in appetite observed in hypoxia. However, reports in the literature present contradictory findings, perhaps due to the use of different experimental paradigms (hypobaric and normobaric hypoxia, active and resting subjects, variability in the degree and duration of hypoxia).
The protocol of the current study standardises physical activity, ambient temperature, hypoxic stimulus and nutritional composition of the diet, and aims to extend our knowledge of the effects of hypoxia and bedrest on appetite and its hormonal control.
In order to discern the separate and combined effects of microgravity and hypoxia, fourteen normal or over-weight men, who are otherwise healthy, will be recruited following medical and psychological screening. They will be invited to attend the Olympic Sport Centre, Planica, Slovenia on 3 occasions, with each visit being 31 days in duration and separated by 5 months. Each 31-day visit ('campaign') includes a baseline recording period (5 days), 21 days of intervention and a recovery period (5 days), with the 3 interventions allocated in a randomized, cross over design: i) Normobaric normoxic bed rest (NBR; FiO2=21%), ii) Normobaric hypoxic ambulatory confinement (HAMB; FiO2=14%; ~4000 m simulated altitude), and iii) Normobaric hypoxic bed rest (HBR; FiO2=14%). A standardized, repeating, 14-day dietary menu, comprised of foods commonly consumed in the Slovenian diet, will be applied during all campaigns, the targeted energy intakes being calculated individually using a modified Benedict-Harris formula with physical activity factor multipliers of 1.2 for the HBR and NBR campaigns and 1.4 for the HAMB campaign. Food will be provided in weighed portions and subjects will be encouraged to eat all food supplied. However, any food not eaten will be weighed and actual amount consumed recorded in a diet analysis programme. Body mass will be assessed daily during the campaigns using a gurney incorporating load cells, and whole body composition will be determined before and immediately after each intervention using fan beam dual-emission X-ray absorptiometry.
Participants will undergo a mixed meal tolerance test before and on day 17 of each intervention period, in the morning, after a 12 hour fast, with the time of assessment replicated on each study day at every campaign. On arrival, participants will rest supine on a hospital bed and place their hand in a heated hand warming unit (air temperature 50-55oC). An intravenous cannula will then be inserted retrograde into a dorsal hand vein for arterialised-venous blood sampling. After 15mins rest, a baseline, fasting blood sample will be taken for determination of serum insulin, total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, adiponectin and leptin, whole blood glucose and lactate, and plasma catecholamines, ghrelin, PeptideYY (PYY), glucagon-like peptide-1(GLP-1), triglycerides, and non-esterified fatty acid concentration. An expired breath sample will be collected into evacuated tubes for 13 labelled carbon dioxide (13CO2) determination, and a 20min baseline measurement of resting energy expenditure (REE) and respiratory exchange ratio (RER) will be then made using indirect calorimetry, with subjects wearing a mask, and both inspired and expired air being measured on every breath. Appetite assessment will be made by asking subjects to rate their hunger, desire to eat, fullness, and their prospective food intake, by placing a vertical mark on a 0-100mm linear scale. This visual analogue scale will be measured from left to right, with 0 indicating no experience of the variable (e.g. not hungry, unable to eat anything) and 100 indicating the most of each variable that they can imagine experiencing (e.g. intense desire to eat, or completely full). Values for these 4 variables will be combined to calculate a combined appetite score (CAS). Once baseline measurements have been completed, subjects will consume a mixed nutrient milkshake (Ensure Plus, Abbott Nutrition) at 5ml/kg body weight, which will be supplemented (at 1% of carbohydrate content) with 13-Carbon labelled (13C) Glucose. Arterialised venous blood samples will subsequently be taken every 10min for glucose and lactate assessment, and every 20min for assessment of serum insulin and incretin hormones. A measurement of REE and RER will be performed in the last 15min of every 30min period for the following 2 hours to assess fuel oxidation and metabolic rate, and an expired breath sample will be collected into evacuated tubes for 13CO2 determination at a later date. Subjective appetite will be assessed every 15minutes throughout using visual analogue scales, as described above, and at the end of the 2hr postprandial period subjects will be given an ad libitum pasta-based test meal and will be instructed to eat until they feel comfortably full. This meal will be comprised of cooked dried white pasta, commercially available tomato-based pasta sauce, olive oil and grated hard cheese, with a composition of 37% of total energy derived from fat, 48% carbohydrate, and 16% protein. The amount eaten will be recorded and related to subjective appetite ratings.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Hypoxic ambulatory | Active comparator | Other: Hypoxic ambulatoryAmbulatory in normobaric hypoxia |
| Hypoxic Bedrest | Experimental | Other: Hypoxic BedrestBedrest in normobaric hypoxia |
| Normoxic bedrest | Active comparator | Other: Normoxic BedrestBedrest in normobaric normoxia |
Who may qualify
- Ages
- 25 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (10 listed)
- Physically and mentally healthy subjects
- Body mass index < 25 kg/m2
- Height 158 - 190 cm
- Waist circumference < 94 cm
- Volunteers that are able to declare their willingness to participate in the entire study
Key exclusion criteria (20 listed)
- Medication required that may interfere with the interpretation of the results
- Bone mineral density (as measured by DEXA) more than 1.5 standard deviations < t score
- Recent sub-standard nutritional status
- Family history of thrombosis or positive response in thrombosis screening procedure.
- (Biochemical analysis of the following parameters: ATIII, High sensitive C-reactive protein, S-Akt., Factor V-Leiden, Prothrombin, Lupus-partial thromboplastin time, Factor II)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hypoxic ambulatory21 days confinement in normobaric hypoxic (FiO2 = 14%) environment | Other | Hypoxic ambulatory |
| Hypoxic Bedrest21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment | Other | Hypoxic Bedrest |
| Normoxic Bedrest21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment | Other | Normoxic bedrest |
Primary outcome
Postprandial whole blood glucose concentration
Time frame: 2hrs
a fasted sample and a sample taken every 10mins for 2hrs following eating, before and after 17days of intervention
18 secondary outcomes
Postprandial serum insulin concentration
Time frame: 2hrs
Postprandial serum C-Peptide concentration
Time frame: 2hrs
Fasting serum leptin concentration
Time frame: early morning fasted sample
Fasting serum adiponectin concentration
Time frame: early morning fasted sample
Fasting serum total cholesterol concentration
Time frame: early morning fasted sample
Fasting serum LDL cholesterol concentration
Time frame: early morning fasted sample
Fasting serum HDL cholesterol concentration
Time frame: early morning fasted sample
Fasting plasmaTriacylglycerol concentration
Time frame: early morning fasted sample
Fasting plasma non-esterified fatty acids concentration
Time frame: early morning fasted sample
Postprandial plasma peptide YY concentration
Time frame: 2hrs
Postprandial plasma Ghrelin concentration
Time frame: 2hrs
Postprandial plasma GLP-1 concentration
Time frame: 2hrs
Postprandial plasma catecholamine concentration
Time frame: 2hrs
Postprandial whole blood lactate concentration
Time frame: 2hrs
postprandial fuel oxidation
Time frame: 2hrs
postprandial resting energy expenditure
Time frame: 2hrs
postprandial subjective appetite
Time frame: 2hrs
postprandial expired 13CO2
Time frame: 2hrs
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Mar 2019.
- Results publication: PubMed 26769956Simpson EJ, Debevec T, Eiken O, Mekjavic I, Macdonald IA. PlanHab: the combined and separate effects of 16 days of bed rest and normobaric hypoxic confinement on circulating lipids and indices of insulin sensitivity in healthy men. J Appl Physiol (1985). 2016 Apr 15;120(8):947-55. doi: 10.1152/japplphysiol.00897.2015. Epub 2016 Jan 14.
- Results publication: PubMed 25091855Debevec T, Bali TC, Simpson EJ, Macdonald IA, Eiken O, Mekjavic IB. Separate and combined effects of 21-day bed rest and hypoxic confinement on body composition. Eur J Appl Physiol. 2014 Nov;114(11):2411-25. doi: 10.1007/s00421-014-2963-1. Epub 2014 Aug 5.
- Results publication: PubMed 27395413Debevec T, Simpson EJ, Mekjavic IB, Eiken O, Macdonald IA. Effects of prolonged hypoxia and bed rest on appetite and appetite-related hormones. Appetite. 2016 Dec 1;107:28-37. doi: 10.1016/j.appet.2016.07.005. Epub 2016 Jul 6.
- Individual participant dataSharing planned: No
Related trials for Hypoxia
Active, not recruitingPhase 1/2
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
Renal Cell Carcinoma
Not yet recruiting
Levetiracetam as an Adjuvant Therapy to Hypothermia in Neonatal Asphyxia
Hypoxic Ischemic Encephalopathy of Newborn, Neuro-protection
RecruitingPhase 1/2
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Renal Cell Carcinoma
Recruiting
Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac Arrest
Out-of-Hospital Cardiac Arrest, Hypoxic-Ischemic Brain Injury
Recruiting
Ventilator Pressure and Optimization of Compliance and Hemodynamics
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Igor Mekjavic, PhD principal investigator
Jozef Stefan Institute
Questions about this trial
What is this clinical trial studying?
A study testing Hypoxic ambulatory, Hypoxic Bedrest and Normoxic Bedrest in people with Hypoxia, run by University of Nottingham.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial whole blood glucose concentration (time frame: 2hrs). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02293772, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2019.